Drug Profile
Palmitoylethanolamide - Prismic Pharmaceuticals
Alternative Names: FSD 201; FSD 201 micro-PEA; FSD-PEA; micro PEA plus pregabalin; micro-palmitoylethanolamide; micro-palmitoylethanolamide (micro-PEA) plus pregabalin; micro-PEA; PP 101; PP 101 micro-PEA; Ultra Micro-Palmitolylethanolamide; ultra-micro PEA; ultra-micronized palmitoyl ethylamine; ultra-micronized PEALatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Epitech Group
- Developer Prismic Pharmaceuticals
- Class Amides; Analgesics; Anti-inflammatories; Antivirals; Cannabinoids; Ethanolamines; Irritable bowel syndrome therapies; Neuroprotectants; Palmitic acids
- Mechanism of Action Cannabinoid receptor agonists; G-protein-coupled receptor 55 modulators; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Musculoskeletal pain
- No development reported Inflammation; Irritable bowel syndrome; Neurological disorders; Pain
- Discontinued COVID 2019 infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA
- 05 Jul 2023 FSD Pharma terminates a phase II trials in Musculoskeletal pain in USA and Canada for business reasons and not for reasons related to safety or efficacy (PO) (NCT05652907)
- 28 May 2023 No recent reports of development identified for preclinical development in Neurological-disorders in USA